Liva Healthcare UK Limited


2020-07-012021-06-302021-06-30false10717560Liva Healthcare UK Limited2021-12-20iso4217:GBPxbrli:pure107175602020-07-01107175602021-06-30107175602020-07-012021-06-30107175602019-07-01107175602020-06-30107175602019-07-012020-06-3010717560bus:SmallEntities2020-07-012021-06-3010717560bus:AuditExempt-NoAccountantsReport2020-07-012021-06-3010717560bus:FullAccounts2020-07-012021-06-3010717560bus:PrivateLimitedCompanyLtd2020-07-012021-06-3010717560core:WithinOneYear2021-06-3010717560core:AfterOneYear2021-06-3010717560core:WithinOneYear2020-06-3010717560core:AfterOneYear2020-06-3010717560core:ShareCapital2021-06-3010717560core:SharePremium2021-06-3010717560core:RevaluationReserve2021-06-3010717560core:OtherReservesSubtotal2021-06-3010717560core:RetainedEarningsAccumulatedLosses2021-06-3010717560core:ShareCapital2020-06-3010717560core:SharePremium2020-06-3010717560core:RevaluationReserve2020-06-3010717560core:OtherReservesSubtotal2020-06-3010717560core:RetainedEarningsAccumulatedLosses2020-06-3010717560core:LandBuildings2021-06-3010717560core:PlantMachinery2021-06-3010717560core:Vehicles2021-06-3010717560core:FurnitureFittings2021-06-3010717560core:OfficeEquipment2021-06-3010717560core:NetGoodwill2021-06-3010717560core:IntangibleAssetsOtherThanGoodwill2021-06-3010717560core:ListedExchangeTraded2021-06-3010717560core:UnlistedNon-exchangeTraded2021-06-3010717560core:LandBuildings2020-06-3010717560core:PlantMachinery2020-06-3010717560core:Vehicles2020-06-3010717560core:FurnitureFittings2020-06-3010717560core:OfficeEquipment2020-06-3010717560core:NetGoodwill2020-06-3010717560core:IntangibleAssetsOtherThanGoodwill2020-06-3010717560core:ListedExchangeTraded2020-06-3010717560core:UnlistedNon-exchangeTraded2020-06-3010717560core:LandBuildings2020-07-012021-06-3010717560core:PlantMachinery2020-07-012021-06-3010717560core:Vehicles2020-07-012021-06-3010717560core:FurnitureFittings2020-07-012021-06-3010717560core:OfficeEquipment2020-07-012021-06-3010717560core:NetGoodwill2020-07-012021-06-3010717560core:IntangibleAssetsOtherThanGoodwill2020-07-012021-06-3010717560core:ListedExchangeTraded2020-07-012021-06-3010717560core:UnlistedNon-exchangeTraded2020-07-012021-06-3010717560core:MoreThanFiveYears2020-07-012021-06-3010717560core:Non-currentFinancialInstruments2021-06-3010717560core:Non-currentFinancialInstruments2020-06-3010717560dpl:CostSales2020-07-012021-06-3010717560dpl:DistributionCosts2020-07-012021-06-3010717560dpl:AdministrativeExpenses2020-07-012021-06-3010717560core:LandBuildings2020-07-012021-06-3010717560core:PlantMachinery2020-07-012021-06-3010717560core:Vehicles2020-07-012021-06-3010717560core:FurnitureFittings2020-07-012021-06-3010717560core:OfficeEquipment2020-07-012021-06-3010717560core:NetGoodwill2020-07-012021-06-3010717560core:IntangibleAssetsOtherThanGoodwill2020-07-012021-06-3010717560dpl:GroupUndertakings2020-07-012021-06-3010717560dpl:ParticipatingInterests2020-07-012021-06-3010717560dpl:GroupUndertakingscore:ListedExchangeTraded2020-07-012021-06-3010717560core:ListedExchangeTraded2020-07-012021-06-3010717560dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2020-07-012021-06-3010717560core:UnlistedNon-exchangeTraded2020-07-012021-06-3010717560dpl:CostSales2019-07-012020-06-3010717560dpl:DistributionCosts2019-07-012020-06-3010717560dpl:AdministrativeExpenses2019-07-012020-06-3010717560core:LandBuildings2019-07-012020-06-3010717560core:PlantMachinery2019-07-012020-06-3010717560core:Vehicles2019-07-012020-06-3010717560core:FurnitureFittings2019-07-012020-06-3010717560core:OfficeEquipment2019-07-012020-06-3010717560core:NetGoodwill2019-07-012020-06-3010717560core:IntangibleAssetsOtherThanGoodwill2019-07-012020-06-3010717560dpl:GroupUndertakings2019-07-012020-06-3010717560dpl:ParticipatingInterests2019-07-012020-06-3010717560dpl:GroupUndertakingscore:ListedExchangeTraded2019-07-012020-06-3010717560core:ListedExchangeTraded2019-07-012020-06-3010717560dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2019-07-012020-06-3010717560core:UnlistedNon-exchangeTraded2019-07-012020-06-3010717560core:NetGoodwill2021-06-3010717560core:IntangibleAssetsOtherThanGoodwill2021-06-3010717560core:LandBuildings2021-06-3010717560core:PlantMachinery2021-06-3010717560core:Vehicles2021-06-3010717560core:FurnitureFittings2021-06-3010717560core:OfficeEquipment2021-06-3010717560core:AfterOneYear2021-06-3010717560core:WithinOneYear2021-06-3010717560core:ListedExchangeTraded2021-06-3010717560core:UnlistedNon-exchangeTraded2021-06-3010717560core:ShareCapital2021-06-3010717560core:SharePremium2021-06-3010717560core:RevaluationReserve2021-06-3010717560core:OtherReservesSubtotal2021-06-3010717560core:RetainedEarningsAccumulatedLosses2021-06-3010717560core:NetGoodwill2020-06-3010717560core:IntangibleAssetsOtherThanGoodwill2020-06-3010717560core:LandBuildings2020-06-3010717560core:PlantMachinery2020-06-3010717560core:Vehicles2020-06-3010717560core:FurnitureFittings2020-06-3010717560core:OfficeEquipment2020-06-3010717560core:AfterOneYear2020-06-3010717560core:WithinOneYear2020-06-3010717560core:ListedExchangeTraded2020-06-3010717560core:UnlistedNon-exchangeTraded2020-06-3010717560core:ShareCapital2020-06-3010717560core:SharePremium2020-06-3010717560core:RevaluationReserve2020-06-3010717560core:OtherReservesSubtotal2020-06-3010717560core:RetainedEarningsAccumulatedLosses2020-06-3010717560core:NetGoodwill2019-07-0110717560core:IntangibleAssetsOtherThanGoodwill2019-07-0110717560core:LandBuildings2019-07-0110717560core:PlantMachinery2019-07-0110717560core:Vehicles2019-07-0110717560core:FurnitureFittings2019-07-0110717560core:OfficeEquipment2019-07-0110717560core:AfterOneYear2019-07-0110717560core:WithinOneYear2019-07-0110717560core:ListedExchangeTraded2019-07-0110717560core:UnlistedNon-exchangeTraded2019-07-0110717560core:ShareCapital2019-07-0110717560core:SharePremium2019-07-0110717560core:RevaluationReserve2019-07-0110717560core:OtherReservesSubtotal2019-07-0110717560core:RetainedEarningsAccumulatedLosses2019-07-0110717560core:AfterOneYear2020-07-012021-06-3010717560core:WithinOneYear2020-07-012021-06-3010717560core:Non-currentFinancialInstrumentscore:CostValuation2020-07-012021-06-3010717560core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2020-07-012021-06-3010717560core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2020-07-012021-06-3010717560core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2020-07-012021-06-3010717560core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2020-07-012021-06-3010717560core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2020-07-012021-06-3010717560core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2020-07-012021-06-3010717560core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2020-07-012021-06-3010717560core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2020-07-012021-06-3010717560core:Non-currentFinancialInstrumentscore:CostValuation2021-06-3010717560core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2021-06-3010717560core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2021-06-3010717560core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2021-06-3010717560core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2021-06-3010717560core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2021-06-3010717560core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2021-06-3010717560core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2021-06-3010717560core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2021-06-3010717560core:Non-currentFinancialInstrumentscore:CostValuation2020-06-3010717560core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2020-06-3010717560core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2020-06-3010717560core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2020-06-3010717560core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2020-06-3010717560core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2020-06-3010717560core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2020-06-3010717560core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2020-06-3010717560core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2020-06-3010717560bus:Director12020-07-012021-06-3010717560bus:Director22020-07-012021-06-3010717560bus:Director32020-07-012021-06-30

Liva Healthcare UK Limited

Registered Number
10717560
(England and Wales)

Unaudited Financial Statements for the Year Ended
30 June 2021

Liva Healthcare UK Limited
Company Information
for the year from 1 July 2020 to 30 June 2021

Directors

R Bech
A Sode
C Sortso

Registered Address

65 Woodbridge Road
Guildford
GU1 4RD

Registered Number

10717560 (England and Wales)
Liva Healthcare UK Limited
Statement of Financial Position
30 June 2021

Notes

2021

2020

£

£

£

£

Fixed assets
Tangible assets97,66811,061
7,66811,061
Current assets
Debtors11182,398260,013
Cash at bank and on hand53,727113,116
236,125373,129
Creditors amounts falling due within one year12(1,553,484)(1,391,965)
Net current assets (liabilities)(1,317,359)(1,018,836)
Total assets less current liabilities(1,309,691)(1,007,775)
Net assets(1,309,691)(1,007,775)
Capital and reserves
Called up share capital11
Profit and loss account(1,309,692)(1,007,776)
Shareholders' funds(1,309,691)(1,007,775)
  • The company was entitled to exemption from audit for this reporting period under section 477 of the Companies Act 2006 relating to small companies.
  • The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
  • The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
  • These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime. The directors have chosen to not file a copy of the company’s profit and loss account.
The financial statements were approved and authorised for issue by the Board of Directors on 20 December 2021, and are signed on its behalf by:
R Bech
Director
Registered Company No. 10717560
Liva Healthcare UK Limited
Notes to the Financial Statements
for the year ended 30 June 2021

1.STATUTORY INFORMATION
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
2.COMPLIANCE WITH APPLICABLE REPORTING FRAMEWORK
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
3.PRINCIPAL ACTIVITIES
The principal activity of the company in the year under review was that of a healthcare app for personal health coaching.
4.SMALLEST GROUP IN WHICH RESULTS ARE CONSOLIDATED
The immediate and ultimate parent during the reporting period is Liva Healthcare A/s, a company incorporated in Denmark with its registered office situated at Danneskiold-Samsoes, Alle 41, Copenhagen K, Dk-1434, Denmark.
5.BASIS OF MEASUREMENT USED IN FINANCIAL STATEMENTS
These financial statements have been prepared in accordance with Financial Reporting Standard 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland including the provisions of Section 1A applicable to Small Entities and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.
6.ACCOUNTING POLICIES
Functional and presentation currency policy
The financial statements are presented in sterling and this is the functional currency of the company.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The statement of financial position is credited with the value of invoiced sales, as deferred income, which is then amortised to revenue over the period of the contract. At the statement of financial position date, the carrying value of deferred income reflects the total value of invoiced sales which has not yet been recognised as revenue.
Property, plant and equipment policy
Tangible assets are stated at cost (or deemed cost), less accumulated depreciation and accumulated impairment losses. Cost includes the original purchase price, costs directly attributable to bringing the asset to its working condition for its intended use, dismantling and restoration costs. Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.




Straight line (years)

Office Equipment3
Revenue recognition policy
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Foreign currency translation and operations policy
Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions. At each reporting period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined. Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at the period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the income statement.
Leases policy
Assets held under finance leases which are leases where substantially all the risks and rewards of ownership of the asset have passed to the company, and hire purchase contracts are capitalised in the statement of financial position. They are depreciated over the shorter of their useful lives or the term of the lease. Rentals paid under operating leases are charged to the income statement on a straight line basis.
Employee benefits policy
Contributions to defined contribution plans are expensed in the period to which they relate.
Valuation of financial instruments policy
The Company has chosen to adopt the Sections 11 and 12 of FRS 102 in respect of financial instruments. The Company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in non puttable ordinary shares. Debt instruments (other than those wholly repayable or receivable within one year), including loans and other accounts receivable and payable, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received. However, if the arrangements of a short term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or financed at a rate of interest that is not a market rate or in case of an out right short term loan not at market rate, the financial asset or liability is measured, initially, at the present value of the future cash flow discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost. Financial assets and liabilities are offset and the net amount reported in the Statement of Financial Position when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. Cash and cash equivalents comprise cash on hand and demand deposits and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk to changes in value.
Going concern
Liva Healthcare UK Limited is currently funded by its Danish parent company, Liva Healthcare A/S, while the company establish its presence and business reach in the UK market. The directors have considered the impact of the COVID 19 pandemic on the activities of the business and do not consider that this will materially impact the ability of the company to trade in future.
7.CRITICAL ESTIMATES AND JUDGEMENTS
There are no significant judgements or estimates applied to the numbers contained within these financial statements.
8.EMPLOYEE INFORMATION




2021



2020

Average number of employees during the year65
9.PROPERTY, PLANT AND EQUIPMENT



Office Equipment
£


Total
£

Cost or valuation
At 01 July 2015,94515,945
Additions2,0292,029
At 30 June 2117,97417,974
Depreciation and impairment
At 01 July 204,8844,884
Charge for year5,4225,422
At 30 June 2110,30610,306
Net book value
At 30 June 217,6687,668
At 30 June 2011,06111,061
10.DESCRIPTION OF NATURE OF TRANSACTIONS AND BALANCES WITH RELATED PARTIES
The company has taken advantage of the exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with other companies within the group.
11.DEBTORS



2021
£


2020
£

Trade debtors / trade receivables127,981220,647
Prepayments and accrued income54,41739,366
Total182,398260,013
12.CREDITORS WITHIN ONE YEAR



2021
£


2020
£

Trade creditors / trade payables8,4634,748
Amounts owed to related parties1,442,5931,227,147
Taxation and social security13,0058,949
Other creditors19,08715,800
Accrued liabilities and deferred income70,336135,321
Total1,553,4841,391,965